Actinium Pharmaceuticals, Inc. (ATNM)

No Data available this quarter, please select a different quarter.

Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.

Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.

Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.

Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.

Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.

No Data available this quarter, please select a different quarter.

Negative OCF growth while TRVN is at 41.66%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.

Negative FCF growth while TRVN is at 41.80%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.

Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.

Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.

Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.

Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.

Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.

Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.

Negative equity/share CAGR over 10 years while TRVN stands at 5596.59%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.

Negative 5Y equity/share growth while TRVN is at 5596.59%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.

Negative 3Y equity/share growth while TRVN is at 5596.59%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

Asset growth well under 50% of TRVN's 124.46%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.

We have a declining book value while TRVN shows 130.43%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.

We’re deleveraging while TRVN stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.

R&D growth drastically higher vs. TRVN's 17.03%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.

SG&A growth well above TRVN's 7.81%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.